Jan 23 (Reuters) - Vigil Neuroscience Inc VIGL.O:
VIGIL NEUROSCIENCE REPORTS POSITIVE DATA FROM ITS PHASE 1 CLINICAL TRIAL EVALUATING VG-3927 FOR THE POTENTIAL TREATMENT OF ALZHEIMER’S DISEASE
VIGIL NEUROSCIENCE INC - VG-3927 TO ADVANCE TO PHASE 2 TRIAL IN Q3 2025
VIGIL NEUROSCIENCE INC - VG-3927 ACHIEVED UP TO 50% REDUCTION OF STREM2 IN CSF
VIGIL NEUROSCIENCE INC - VG-3927 SHOWED FAVORABLE SAFETY AND TOLERABILITY PROFILE
Source text: ID:nGNXqgh0d
Further company coverage: VIGL.O
((Reuters.Briefs@thomsonreuters.com;))
免責聲明:投資有風險,本文並非投資建議,以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請,作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考,不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證,投資者應自行研究並在投資前尋求專業建議。